A Ligand-mediated Hydrogen Bond Network Required for the Activation of the Mineralocorticoid Receptor*[boxs]

Ligand binding is the first step in hormone regulation of mineralocorticoid receptor (MR) activity. Here, we report multiple crystal structures of MR (NR3C2) bound to both agonist and antagonists. These structures combined with mutagenesis studies reveal that maximal receptor activation involves an intricate ligand-mediated hydrogen bond network with Asn770 which serves dual roles: stabilization of the loop preceding the C-terminal activation function-2 helix and direct contact with the hormone ligand. In addition, most activating ligands hydrogen bond to Thr945 on helix 10. Structural characterization of the naturally occurring S810L mutant explains how stabilization of a helix 3/helix 5 interaction can circumvent the requirement for this hydrogen bond network. Taken together, these results explain the potency of MR activation by aldosterone, the weak activation induced by progesterone and the antihypertensive agent spironolactone, and the binding selectivity of cortisol over cortisone.

[1]  E. D. de Kloet,et al.  Mineralocorticoid receptor ligands: Biochemical, pharmacological, and clinical aspects , 1991, Medicinal research reviews.

[2]  A. Vandewalle,et al.  Identification of steroid ligands able to inactivate the mineralocorticoid receptor harboring the S810L mutation responsible for a severe form of hypertension , 2004, Molecular and Cellular Endocrinology.

[3]  M. Lombès,et al.  New naturally occurring missense mutations of the human mineralocorticoid receptor disclose important residues involved in dynamic interactions with deoxyribonucleic acid, intracellular trafficking, and ligand binding. , 2004, Molecular endocrinology.

[4]  T. Willson,et al.  Crystal Structure of the Glucocorticoid Receptor Ligand Binding Domain Reveals a Novel Mode of Receptor Dimerization and Coactivator Recognition , 2002, Cell.

[5]  K. Weber,et al.  Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. , 1992, The Journal of laboratory and clinical medicine.

[6]  F. Holsboer,et al.  Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands. , 1993, European journal of pharmacology.

[7]  N. Farman,et al.  Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart. , 1995, Circulation.

[8]  K. Geering,et al.  Mechanism of the antimineralocorticoid effects of spirolactones. , 1981, Kidney international.

[9]  C. Edwards,et al.  The cortisol-cortisone shuttle and hypertension , 1991, The Journal of Steroid Biochemistry and Molecular Biology.

[10]  P. Sigler,et al.  Atomic structure of progesterone complexed with its receptor , 1998, Nature.

[11]  M. Quinkler,et al.  The human kidney is a progesterone-metabolizing and androgen-producing organ. , 2003, The Journal of clinical endocrinology and metabolism.

[12]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[13]  S. Oparil,et al.  Desoxycorticosterone in normal pregnancy. I. Sequential studies of the secretory patterns of desoxycorticosterone, aldosterone, and cortisol. , 1978, American journal of obstetrics and gynecology.

[14]  D. Moras,et al.  Antagonism in the human mineralocorticoid receptor , 1998, The EMBO journal.

[15]  R. Salomon,et al.  Different inactivating mutations of the mineralocorticoid receptor in fourteen families affected by type I pseudohypoaldosteronism. , 2003, Journal of Clinical Endocrinology and Metabolism.

[16]  M. Agarwal,et al.  General overview of mineralocorticoid hormone action. , 1999, Pharmacology & therapeutics.

[17]  M. Quinkler,et al.  Enzyme-mediated protection of the mineralocorticoid receptor against progesterone in the human kidney , 2001, Molecular and Cellular Endocrinology.

[18]  D. Feldman,et al.  Molecular modifications of anti-aldosterone compounds: effects on affinity of spirolactones for renal aldosterone receptors. , 1974, Biochemical pharmacology.

[19]  D. Armanini,et al.  Inactivating mutations of the mineralocorticoid receptor in Type I pseudohypoaldosteronism , 2004, Molecular and Cellular Endocrinology.

[20]  D. Housman,et al.  Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. , 1987, Science.

[21]  C. Hellal-Levy,et al.  Mechanistic aspects of mineralocorticoid receptor activation. , 2000, Kidney international.

[22]  P. Corvol,et al.  Importance of the lactonic ring in the activity of steroidal antialdosterones. , 1980, Biochemical pharmacology.

[23]  E. Johansson,et al.  Progesterone Levels in Amniotic Fluid and Plasma from Women I. Levels during Normal Pregnancy , 1971, Acta obstetricia et gynecologica Scandinavica.

[24]  A. Vandewalle,et al.  The severe form of hypertension caused by the activating S810L mutation in the mineralocorticoid receptor is cortisone related. , 2003, Endocrinology.

[25]  Zbigniew Dauter,et al.  Molecular basis of agonism and antagonism in the oestrogen receptor , 1997, Nature.

[26]  P. Sigler,et al.  Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. , 2000, Science.

[27]  J. Funder,et al.  Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. , 1988, Science.

[28]  Junhui Zhang,et al.  A critical role of helix 3-helix 5 interaction in steroid hormone receptor function. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Peter Scholz,et al.  Structural Evidence for Ligand Specificity in the Binding Domain of the Human Androgen Receptor , 2000, The Journal of Biological Chemistry.

[30]  A. B. Maksymowych,et al.  Overexpression and characterization of the human mineralocorticoid receptor. , 1991, The Journal of biological chemistry.

[31]  A. Vandewalle,et al.  11β-Hydroxyprogesterone Acts as a Mineralocorticoid Agonist in Stimulating Na+ Absorption in Mammalian Principal Cortical Collecting Duct Cells , 2002 .

[32]  R J Fletterick,et al.  Structure and specificity of nuclear receptor-coactivator interactions. , 1998, Genes & development.

[33]  M. Quinkler,et al.  Expression of the progesterone receptor and progesterone- metabolising enzymes in the female and male human kidney. , 2002, The Journal of endocrinology.

[34]  Howard M. Einspahr,et al.  Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[35]  T. Willson,et al.  Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ , 1998, Nature.

[36]  R. Evans,et al.  The steroid and thyroid hormone receptor superfamily. , 1988, Science.

[37]  D. Moras,et al.  A single amino acid mutation of ala-773 in the mineralocorticoid receptor confers agonist properties to 11beta-substituted spirolactones. , 2000, Molecular pharmacology.

[38]  K. Umesono,et al.  A Unified Nomenclature System for the Nuclear Receptor Superfamily , 1999, Cell.

[39]  Jonathan Greer,et al.  The Three-dimensional Structures of Antagonistic and Agonistic Forms of the Glucocorticoid Receptor Ligand-binding Domain , 2003, Journal of Biological Chemistry.

[40]  M. Young,et al.  Mineralocorticoid receptors and pathophysiological roles for aldosterone in the cardiovascular system. , 2002, Journal of hypertension.